A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to provide data on the dose response of simvastatin in lowering LDL-C when it is co-administered with valsartan in patients with both essential hypertension and hypercholesterolemia. The primary objective of the study will be to show that the combination of valsartan 160mg/simvastatin 40mg has superior efficacy compared to the combination of valsartan 160mg/simvastatin 20mg in percentage change from baseline in LDL-C.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Simvastatin; Valsartan

Criteria

Inclusion Criteria:

• Elevated LDL-Cholesterol

• Essential hypertension

Exclusion Criteria:

• Severe Hypertension

• Prior or known muscular or neuromuscular disease of any type

• A history of cardiovascular disease

• Hypertension or hypercholesterolemia due to secondary causes

• Uncontrolled diabetes or insulin treatment

• Evidence of hepatic or renal disease

Other protocol-defined exclusion criteria may apply